Kaposi’s sarcoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:13:33 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Kaposi’s sarcoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Pembrolizumab and Lenvatinib for Patients with Classic Kaposi Sarcoma After Previous Treatment https://clinicaltrials.eu/trial/study-of-pembrolizumab-and-lenvatinib-for-patients-with-classic-kaposi-sarcoma-after-previous-treatment/ Wed, 29 Apr 2026 15:02:10 +0000 https://clinicaltrials.eu/trial/study-of-pembrolizumab-and-lenvatinib-for-patients-with-classic-kaposi-sarcoma-after-previous-treatment/ This clinical trial is focused on studying a treatment for classic Kaposi sarcoma, a type of cancer that affects the skin, mouth, and sometimes internal organs. The study involves patients who have already received at least one previous treatment for their condition. The treatment being tested combines two medications: pembrolizumab and lenvatinib. Pembrolizumab is given as an infusion, which means it is administered directly into the bloodstream through a vein, while lenvatinib is taken orally in the form of capsules.

The purpose of the study is to evaluate how well this combination of medications works in treating patients with classic Kaposi sarcoma that has returned or not responded to standard treatments. Participants in the study will receive both pembrolizumab and lenvatinib over a period of up to 24 months. During this time, doctors will monitor the patients’ response to the treatment, including any changes in their health and quality of life. The study will also look at how long the treatment effects last and how safe and tolerable the medications are for the patients.

Throughout the study, various tests and assessments will be conducted to gather information about the patients’ health and the effectiveness of the treatment. This includes checking for changes in specific markers in the blood and examining tissue samples from the cancer. The study aims to provide valuable insights into the potential benefits of using pembrolizumab and lenvatinib together for treating classic Kaposi sarcoma.

]]> Study of Pembrolizumab for Patients with Classic or Endemic Kaposi’s Sarcoma https://clinicaltrials.eu/trial/study-of-pembrolizumab-for-patients-with-classic-or-endemic-kaposis-sarcoma/ Wed, 29 Apr 2026 14:22:46 +0000 https://clinicaltrials.eu/trial/study-of-pembrolizumab-for-patients-with-classic-or-endemic-kaposis-sarcoma/ This clinical trial is focused on studying a disease called Kaposi’s sarcoma, which is a type of cancer that forms in the skin, lymph nodes, or other organs. The study is investigating the effects of a treatment called pembrolizumab, which is a medication given through an infusion into the vein. Pembrolizumab is a type of protein that helps the immune system fight cancer cells.

The purpose of the study is to determine if pembrolizumab is effective in treating classic or endemic Kaposi’s sarcoma. Participants in the study will receive pembrolizumab and will be monitored to see how their disease responds to the treatment. The study will look at how many patients experience a reduction in their cancer, either partially or completely, over a period of time. This will help researchers understand if pembrolizumab can be a useful treatment for this type of cancer.

Throughout the study, participants will receive regular infusions of pembrolizumab and will have their health closely monitored by the research team. The study will last for several months, and participants will be checked regularly to see how their cancer is responding to the treatment. The information gathered from this study will contribute to understanding the potential benefits of pembrolizumab for patients with Kaposi’s sarcoma.

]]>